NLIGHT, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that NLIGHT, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $46.16M | Mar 15, 2019 |
| FY2018 | Sep 30, 2018 | $51.03M | Mar 15, 2019 |
| FY2018 | Jun 30, 2018 | $51.71M | Mar 15, 2019 |
| FY2018 | Mar 31, 2018 | $42.47M | Mar 15, 2019 |
| FY2018 | Dec 31, 2017 | $37.48M | Mar 15, 2019 |
| FY2018 | Sep 30, 2017 | $36.55M | Mar 15, 2019 |
| FY2018 | Jun 30, 2017 | $34.66M | Mar 15, 2019 |
| FY2018 | Mar 31, 2017 | $29.89M | Mar 15, 2019 |
| FY2018 | Dec 31, 2016 | $101.33M | Mar 15, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $261.33M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $198.55M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $209.92M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $242.06M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $270.15M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $222.79M | Feb 27, 2023 |
| FY2019 | Dec 31, 2019 | $42.90M | Mar 9, 2020 |
| FY2019 | Sep 30, 2019 | $43.81M | Mar 9, 2020 |
| FY2019 | Jun 30, 2019 | $48.05M | Mar 9, 2020 |
| FY2019 | Mar 31, 2019 | $41.86M | Mar 9, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $77.96M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $33.02M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $46.11M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $50.82M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $77.31M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $59.36M | Feb 27, 2023 |
| FY2019 | Dec 31, 2019 | $9.99M | Mar 9, 2020 |
| FY2019 | Sep 30, 2019 | $12.96M | Mar 9, 2020 |
| FY2019 | Jun 30, 2019 | $15.87M | Mar 9, 2020 |
| FY2019 | Mar 31, 2019 | $13.51M | Mar 9, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($23.47M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($60.79M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | ($41.67M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | ($54.58M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | ($29.67M) | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | ($20.93M) | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | ($12.88M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $13.94M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $1.84M | Mar 9, 2020 |
| FY2018 | Dec 31, 2016 | ($14.20M) | Mar 15, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($26.55M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($65.64M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | ($46.77M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | ($55.10M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | ($30.22M) | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | ($21.05M) | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | ($9.91M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $17.06M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $9.80M | Mar 9, 2020 |
| FY2018 | Dec 31, 2016 | ($9.34M) | Mar 15, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $47.97M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $45.11M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $46.16M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $53.77M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $54.81M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $41.16M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $28.14M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $21.05M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $15.12M | Mar 9, 2020 |
| FY2018 | Dec 31, 2016 | $15.24M | Mar 15, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $54.19M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $49.26M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $45.90M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $48.26M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $52.71M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $39.25M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $34.11M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $28.84M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $19.35M | Mar 9, 2020 |
| FY2018 | Dec 31, 2016 | $17.27M | Mar 15, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.33M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($2.36M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $10.09M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | ($14.54M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | ($7.44M) | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $13.04M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | ($4.24M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $3.38M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $3.41M | Mar 9, 2020 |
| FY2018 | Dec 31, 2016 | $5.96M | Mar 15, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.03M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $7.93M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $5.34M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $21.39M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $19.32M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $23.42M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $12.40M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $10.58M | Feb 26, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $315.21M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $270.24M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $306.80M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $329.23M | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $373.62M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $283.64M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $249.97M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $250.13M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $110.15M | Mar 15, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $88.46M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $53.81M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $52.38M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $58.39M | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $71.49M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $63.73M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $33.36M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $32.35M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $48.87M | Mar 15, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $226.75M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $216.43M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $254.42M | Feb 27, 2026 |
| FY2025 | Dec 31, 2022 | $270.85M | Feb 27, 2026 |
| FY2024 | Dec 31, 2021 | $302.13M | Feb 28, 2025 |
| FY2023 | Dec 31, 2020 | $219.91M | Feb 26, 2024 |
| FY2022 | Dec 31, 2019 | $216.61M | Feb 27, 2023 |
| FY2021 | Dec 31, 2018 | $217.78M | Feb 28, 2022 |
| FY2020 | Dec 31, 2017 | $61.28M | Feb 26, 2021 |
| FY2019 | Dec 31, 2016 | $29.69M | Mar 9, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.45M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $12.35M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $12.40M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $12.38M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $12.42M | Feb 26, 2024 |
| FY2021 | Dec 31, 2020 | $12.48M | Feb 28, 2022 |
| FY2021 | Dec 31, 2019 | $9.87M | Feb 28, 2022 |
| FY2019 | Dec 31, 2018 | $1.39M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $1.39M | Mar 15, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($348.56M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($325.10M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | ($264.30M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($222.63M) | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | ($168.06M) | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | ($138.39M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | ($117.45M) | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | ($104.73M) | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | ($118.67M) | Mar 15, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $98.70M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $65.83M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $53.21M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $57.83M | Feb 28, 2025 |
| FY2022 | Dec 31, 2021 | $146.53M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $102.28M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $117.25M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $149.48M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $36.69M | Mar 15, 2019 |
| FY2018 | Dec 31, 2016 | $13.50M | Mar 15, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $109.0K | Mar 15, 2019 |
| FY2018 | Dec 31, 2017 | $17.47M | Mar 15, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 27, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Mar 9, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Mar 9, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Mar 9, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Mar 9, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 27, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Mar 9, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Mar 9, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Mar 9, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Mar 9, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 51.16M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 48.95M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | 47.27M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | 45.63M | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | 44.25M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | 39.79M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | 38.08M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | 36.71M | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | 2.98M | Mar 15, 2019 |